Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
Total Valuation
Oric Pharmaceuticals has a market cap or net worth of $973.89M. The enterprise value is $903.60M.
Market Cap$973.89M
Enterprise Value$903.60M
Share Statistics
Oric Pharmaceuticals has 97,389,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding97,389,280
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Oric Pharmaceuticals’s return on equity (ROE) is -0.53 and return on invested capital (ROIC) is -55.89%.
Return on Equity (ROE)-0.53
Return on Assets (ROA)-0.47
Return on Invested Capital (ROIC)-55.89%
Return on Capital Employed (ROCE)-0.57
Revenue Per Employee0.00
Profits Per Employee-1.05M
Employee Count122
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oric Pharmaceuticals is ―. Oric Pharmaceuticals’s PEG ratio is 0.66.
PE Ratio―
PS Ratio0.00
PB Ratio2.31
Price to Fair Value2.31
Price to FCF-4.94
Price to Operating Cash Flow-10.24
PEG Ratio0.66
Income Statement
In the last 12 months, Oric Pharmaceuticals had revenue of 0.00 and earned -127.85M in profits. Earnings per share was -1.83.
Revenue0.00
Gross Profit-1.11M
Operating Income-142.90M
Pretax Income-127.85M
Net Income-127.85M
EBITDA-126.74M
Earnings Per Share (EPS)-1.83
Cash Flow
In the last 12 months, operating cash flow was -116.78M and capital expenditures -704.00K, giving a free cash flow of -117.49M billion.
Operating Cash Flow-116.78M
Free Cash Flow-117.49M
Free Cash Flow per Share-1.21
Dividends & Yields
Oric Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.40
52-Week Price Change13.83%
50-Day Moving Average12.26
200-Day Moving Average9.44
Relative Strength Index (RSI)27.50
Average Volume (3m)1.19M
Important Dates
Oric Pharmaceuticals upcoming earnings date is Mar 24, 2026, After Close (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 24, 2026
Ex-Dividend Date―
Financial Position
Oric Pharmaceuticals as a current ratio of 10.56, with Debt / Equity ratio of 0.00%
Current Ratio10.56
Quick Ratio10.56
Debt to Market Cap<0.01
Net Debt to EBITDA0.39
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oric Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Oric Pharmaceuticals EV to EBITDA ratio is -4.04, with an EV/FCF ratio of -4.50.
EV to Sales0.00
EV to EBITDA-4.04
EV to Free Cash Flow-4.50
EV to Operating Cash Flow-4.55
Balance Sheet
Oric Pharmaceuticals has $287.14M in cash and marketable securities with $3.30M in debt, giving a net cash position of $283.84M billion.
Cash & Marketable Securities$287.14M
Total Debt$3.30M
Net Cash$283.84M
Net Cash Per Share$2.91
Tangible Book Value Per Share$3.49
Margins
Gross margin is -7.41%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-7.41%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oric Pharmaceuticals is $19.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$19.33
Price Target Upside106.08% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast―
EPS Growth Forecast4.29%